In this letter, we discussed that HbA1c/C-peptide ratio is a potential biomarker used to predict no-reflow phenomenon in patients with ST-elevation myocardial infarction.
ToprakKKaplangorayMMemioğluT, et al.The HbA1c/C-peptide ratio is associated with the no-reflow phenomenon in patients with ST-elevation myocardial infarction. Angiology2025;76:289-299.
2.
NiccoliGMontoneRAIbanezB, et al.Optimized treatment of ST-elevation myocardial infarction. Circ Res2019;125:245-258.
3.
LawtonJSTamis-HollandJEBangaloreS, et al.ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e4-17.
4.
JaffeRCharronTPuleyGDickAStraussBH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation2008;117:3152-3156.
5.
NdrepepaGTirochKFusaroM, et al.5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol2010;55:2383-2389.
6.
RezkallaSHStankowskiRVHannaJKlonerRA. Management of no-reflow phenomenon in the catheterization laboratory. JACC Cardiovasc Interv2017;10:215-223.
7.
SafakOYildirimTEmrenV, et al.Prognostic nutritional index as a predictor of no-reflow occurrence in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention. Angiology2024;75:689-695.
8.
NurkoçSGKarayiğitO. The Association between no-reflow and serum uric acid/albumin ratio in patients with acute myocardial infarction without ST elevation. Angiology2024;75:72-78.
9.
ÇelikMCKarayiğitOOzkanCDoluAKKalçıkM. Relationship between systemic inflammation index and no-reflow phenomenon in patients with ST-segment elevation myocardial infarction. Angiology2023;74:387-394.
10.
LeeSLiuTZhouJZhangQWongWTTseG. Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study. Acta Diabetol2021;58:171-180.
11.
WangNWangYZhangW, et al.C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes. Diabetes Metab Res Rev2020;36:e3210.
12.
ZhaoSRHuangRLiuFLiYGongYXingJ. Study on correlation between type 2 diabetes and no-reflow after PCI. Dis Markers2022;2022:7319277.
